Researchers have identified andrographolide, a natural diterpenoid derived from the plant Andrographis paniculata, as the first reported small-molecule compound that directly targets succinate dehydrogenase complex flavoprotein subunit A (SDHA). Published in Cellular & Molecular Biology Letters, the study demonstrates that this interaction disrupts the assembly of SDHA with succinate dehydrogenase complex assembly factor 4 (SDHAF4), thereby compromising mitochondrial metabolic homeostasis. This disruption promotes ferroptosis, an iron-dependent and lipid peroxidation-driven form of regulated cell death, and significantly enhances the sensitivity of triple-negative breast cancer (TNBC) cells to doxorubicin (DOX), a standard chemotherapy agent to which TNBC is often refractory.
The study addresses a critical gap in oncology where TNBC remains highly resistant to anthracyclines like doxorubicin due to apoptosis-associated resistance mechanisms. While ferroptosis has emerged as a promising strategy to circumvent this apoptotic escape, clinically actionable targets for inducing this form of cell death in TNBC have remained poorly defined. Specifically, the role of mitochondrial complex II assembly in governing ferroptosis and chemoresistance had not been previously elucidated, and no small-molecule compound had been reported to directly target SDHA or disrupt its interaction with SDHAF4.
To identify the molecular target of andrographolide, the researchers employed a suite of biochemical and biophysical techniques, including drug affinity responsive target stability (DARTS), cellular thermal shift assay (CETSA), and mass spectrometry. Further validation was achieved through pull-down assays, surface plasmon resonance (SPR), and molecular docking simulations. The disruption of the SDHA–SDHAF4 complex was examined using co-immunoprecipitation and molecular dynamics simulation, while nuclear protein isolation and confocal microscopy were utilized to determine nuclear localization. Additionally, protein succinylation was analyzed to understand post-translational modifications associated with the compound’s activity. Ferroptosis responses were comprehensively assessed through transmission electron microscopy, lipid peroxidation assays, and measurements of intracellular Fe2+, malondialdehyde (MDA), glutathione (GSH), and reactive oxygen species (ROS).
The results revealed that andrographolide potently induced ferroptosis, inhibited TNBC cell proliferation, and enhanced DOX sensitivity in both two-dimensional TNBC cell lines and three-dimensional patient-derived organoids. Mechanistically, andrographolide increased lipid peroxidation, Fe2+ accumulation, ROS, and MDA levels, effects that were attenuated by ferroptosis inhibitors or ROS scavengers. Structural and biochemical analyses indicated that andrographolide binds at Arg451 and His407 on SDHA, disrupting the SDHA–SDHAF4 interaction. This binding impairs SDHA maturation and destabilizes complex II assembly, identifying SDHA as a direct molecular target of the compound. In vivo studies further demonstrated that andrographolide synergized with doxorubicin to suppress TNBC tumor growth without detectable systemic toxicity.
Importantly, the study is the first to demonstrate that the integrity of SDHA–SDHAF4 assembly serves as a critical metabolic checkpoint governing ferroptosis sensitivity and chemoresistance. Disruption of this assembly triggered two convergent ferroptotic signals: excessive ROS generation and succinate accumulation-mediated Keap1 succinylation. The findings suggest that the stability of the SDHA–SDHAF4 complex is not merely a structural feature but a functional regulator of mitochondrial metabolic homeostasis that influences the susceptibility of cancer cells to ferroptotic cell death.
Similar chemosensitizing effects of andrographolide were observed in lung and stomach cancer models, consistent with the broader implications of SDHA targeting in chemoresistant cancers. Notably, SDHA knockdown further amplified andrographolide-induced ferroptosis, reinforcing the central role of SDHA in the compound’s mechanism of action. These observations highlight a previously unrecognized SDHA-centered metabolic vulnerability that can be therapeutically exploited to induce ferroptosis and overcome doxorubicin resistance in TNBC.
The study concludes that andrographolide represents a novel natural small-molecule inhibitor that targets SDHA and disrupts SDHA–SDHAF4 assembly. By revealing that SDHA–SDHAF4 complex integrity governs ferroptosis susceptibility and anthracycline resistance, the research uncovers a new avenue for therapeutic intervention in triple-negative breast cancer. The ability of andrographolide to enhance doxorubicin sensitivity without significant systemic toxicity suggests its potential as a chemosensitizer in combination therapy.
Subject of Research: Mechanistic role of andrographolide in targeting SDHA to induce ferroptosis in triple-negative breast cancer
Article Title: Andrographolide disrupts SDHA–SDHAF4 assembly-mediated mitochondrial metabolic homeostasis to promote ferroptosis and doxorubicin sensitivity in triple-negative breast cancer
Article References: Feng, Z., Zhao, P., Cui, H., Choi, S. B., Zhou, T., Hong, Y., Zhou, L., Chen, M., Song, H., Hao, X., & Yang, J. (2026). Andrographolide disrupts SDHA–SDHAF4 assembly-mediated mitochondrial metabolic homeostasis to promote ferroptosis and doxorubicin sensitivity in triple-negative breast cancer. Cellular & Molecular Biology Letters. https://doi.org/10.1186/s11658-026-01016-5
Image Credits: AI Generated
DOI: 10.1186/s11658-026-01016-5
Keywords: triple-negative breast cancer, andrographolide, ferroptosis, SDHA, SDHAF4, doxorubicin, mitochondrial metabolism, chemoresistance, small-molecule inhibitor, Cellular & Molecular Biology Letters, disrupts, assembly-mediated
News Source: Nathaniel Bowman. (November 7, 2026). Andrographolide Targets SDHA to Boost Cancer Drug Sensitivity. Scienmag.



